Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Researchers discover new class of drugs that could treat retinal dystrophies ➤ Enrollment complete in Phase 1/2a study using novel dry eye treatment approach ➤ NDA submitted to FDA for investigational inflammation and pain treatment ➤ Study: first-in-human gene therapy trial for achromatopsia ➤ ASCRS news and events
➤ FDA approves ophthalmic spray for mydriasis ➤ FDA accepts NDA for travoprost intraocular implant ➤ FDA accepts supplemental BLA for treatment for macular edema ➤ FDA 510(k) clearance granted to green pattern laser photocoagulator ➤ NDA submitted for pain and inflammation nanoemulsion ➤ Positive clinical results from IOP-monitoring contact lens ➤ Study provides real-world data comparing MIGS using IRIS Registry ➤ FDA approves IOL positioning system ➤ ASCRS news and events
➤ Topline data from Phase 3 presbyopia drop trial ➤ Femtosecond laser for LASIK receives FDA clearance ➤ Enrollment complete for hydrophobic trifocal IOL trial ➤ Early results from clinical trial for dry eye therapy ➤ FDA clears IND application for clinical trial of therapy for X-linked retinoschisis ➤ Innovations in capsulotomy creation device ➤ Company acquisition news ➤ ASCRS news and events
➤ FDA approves new monofocal IOL ➤ Topline Phase 3 results for fixed-dose combination presbyopia drop ➤ Gene therapy trial produces positive Phase 1/2 data for Leber congenital amaurosis ➤ New data shows investigational compound protects endothelium for cataract patients undergoing Fuchs treatment ➤ ASCRS news and events
➤ First in-human, non-invasive femtosecond laser trabeculotomy data ➤ Special Protocol Assessment received for Phase 2b/3 trial for dry AMD treatment ➤ FDA gives clearance to IND for geographic atrophy treatment ➤ Positive preliminary data in trial for retinitis pigmentosa and Leber congenital amaurosis therapy ➤ Wet AMD treatment proceeds to Phase 2 trial ➤ ASCRS news and events
➤ Fast-Track Designation granted for persistent epithelial defect treatment ➤ Study: automated capsulotomy device and white cataracts ➤ Dose escalation complete for Phase 1/2 study evaluating an RP treatment ➤ Companies enter agreement for sustained-release glaucoma treatment ➤ ASCRS news and events
➤ FDA approves twice-daily use of presbyopia drop ➤ Study: drug approved for high blood pressure shows promise for blinding childhood disease ➤ Breakthrough device designation granted to investigational dry AMD therapy ➤ Positive topline results for Phase 2 study of retinitis pigmentosa treatment ➤ FDA approves pediatric enrollment in trial for retinitis pigmentosa and Leber congenital amaurosis ➤ ASCRS news and events
➤ Patient enrollment complete for sustained release AMD therapy trial ➤ First patient dosed with corneal endothelial cell substitute ➤ First patient dosed in RNAi therapy for wet and dry AMD ➤ Study: early signs of corneal graft rejection reversed with steroid nanoparticle ➤ Company announces anti-VEGF market tracker ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Allogenic cell therapy receives regulatory approval for bullous keratopathy indication ➤ 24-month data on AMD photobiomodulation therapy ➤ Patient enrollment complete for Phase 3 trial evaluating topical presbyopia treatment ➤ Pre-IND meeting for treatment of corneal endothelial disease ➤ IND submitted for geographic atrophy treatment ➤ Second Phase 3 trial for dry eye disease therapy ➤ ASCRS news and events
➤ Positive preclinical results for non-viral gene therapy platform ➤ Real-world data confirms efficacy of investigational LHON therapy ➤ Largest genome wide study of photoreceptor cells to date ➤ CDC continues to investigate infectious outbreak associated with artificial tear use ➤ Updates from AAV-based gene therapy program for retinal conditions ➤ ASCRS news and events